US 11,986,517 B2
Cancer vaccines targeting mesothelin and uses thereof
Jian Yan, Wallingford, PA (US); Anna Slager, Lansdale, PA (US); Bradley Garman, Glenside, PA (US); and Neil Cooch, Oreland, PA (US)
Assigned to Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA (US)
Filed by Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA (US)
Filed on Sep. 7, 2021, as Appl. No. 17/467,728.
Application 17/467,728 is a division of application No. 16/219,287, filed on Dec. 13, 2018, granted, now 11,154,602.
Claims priority of provisional application 62/598,289, filed on Dec. 13, 2017.
Prior Publication US 2021/0401959 A1, Dec. 30, 2021
Int. Cl. A61K 39/39 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)
CPC A61K 39/001168 (2018.08) [A61K 39/39 (2013.01); A61P 35/00 (2018.01); A61K 2039/53 (2013.01); A61K 2039/55527 (2013.01); A61K 2039/55538 (2013.01)] 3 Claims
 
1. A protein comprising the amino acid sequence selected from the group consisting of:
(a) amino acids 19-607 of SEQ ID NO: 2;
(b) an amino acid sequence that is at least 96% identical to amino acids 19-607 of SEQ ID NO: 2, wherein the protein comprises an alanine at amino acid position 303, a threonine at amino acid position 583, and a valine at amino acid position 585 relative to SEQ ID NO: 2.